田口 和明 (タグチ カズアキ)

Taguchi, Kazuaki

写真a

所属(所属キャンパス)

薬学部 薬学科 薬効解析学講座 (芝共立)

職名

専任講師

経歴 【 表示 / 非表示

  • 2010年04月
    -
    2011年03月

    日本学術振興会特別研究員

  • 2011年04月
    -
    2013年03月

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013年04月
    -
    2017年03月

    崇城大学 , 薬学部, 助教

  • 2018年04月
    -
    継続中

    慶應義塾大学, 薬学部, 専任講師

学歴 【 表示 / 非表示

  • 2006年03月

    熊本大学, 薬学部

    大学, 卒業

  • 2008年03月

    熊本大学

    大学院, 修了, 博士前期

  • 2011年03月

    熊本大学

    大学院, 修了, 博士後期

学位 【 表示 / 非表示

  • 博士 (薬学), 熊本大学, 2011年03月

免許・資格 【 表示 / 非表示

  • 薬剤師, 2006年04月

 

著書 【 表示 / 非表示

  • DDS先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017年

    担当範囲: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015年

    担当範囲: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013年

    担当範囲: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013年

    担当範囲: Chapter 6, pp.139-62

論文 【 表示 / 非表示

  • Azoles versus conventional amphotericin B for the treatment of candidemia: A meta-analysis of randomized controlled trials.

    Osa S, Tashiro S, Igarashi Y, Watabe Y, Liu X, Enoki Y, Taguchi K, Mayumi T, Miyazaki Y, Takesue Y, Matsumoto K

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 26 ( 11 ) 1232 - 1236 2020年11月

    ISSN  1341-321X

  • Echinocandins versus non-echinocandins for the treatment of invasive candidiasis: A meta-analysis of randomized controlled trials

    Tashiro S., Osa S., Igarashi Y., Watabe Y., Liu X., Enoki Y., Taguchi K., Mayumi T., Miyazaki Y., Takesue Y., Matsumoto K.

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  26 ( 11 ) 1164 - 1176 2020年11月

    ISSN  1341321X

     概要を見る

    © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Introduction: Echinocandins are frequent use antifungals in the treatment of invasive candidiasis, and it is important to update information on their efficacy and safety for optimal antifungal drug treatment. The aim of this study is to clarify whether echinocandins are superior to non-echinocandins for the treatment of invasive candidiasis. Methods: We conducted a meta-analysis of RCTs of echinocandins and non-echinocandins for adult invasive candidiasis. The MEDLINE, Web of Sciences, Cochrane Register of Controlled Trials, and ClinicalTrials.gov databases before June 2019 were used. The risk ratio (RR) and 95% confidence interval (95% CI) were calculated using the Mantel-Haenszel method random-effects model. Results: We identified 14,846 articles and screened, and five studies were included meta-analysis. The treatment success ratio for echinocandins was significantly higher than that for non-echinocandins (RR = 1.14, 95% CI 1.06–1.22, p = 0.0003). In regard to adverse events, there was no significant difference between the two treatment groups. A subgroup analysis showed that the treatment success ratio for echinocandins was significantly higher than that for azoles (RR = 1.20, 1.08–1.34, p = 0.001), whereas no significant differences were observed between echinocandins and polyenes. In safety analysis, the incidence ratio of electrolyte disorder (RR = 0.50, 0.33–0.76, p = 0.001), renal disorder (RR = 0.19, 0.09–0.40, p < 0.0001), and fever (RR = 0.46, 0.23–0.93, p = 0.03) were significantly lower in patients receiving echinocandins than in those receiving polyenes. Conclusions: This meta-analysis based on RCTs was first to show that use of echinocandins was associated with improved clinical success. Echinocandins may be useful as a first-line drug for invasive candidiasis.

  • Characterization of the Interaction of Daptomycin With Site II on Human Serum Albumin

    Yamasaki K., Sakurama K., Nishi K., Watanabe H., Maruyama T., Seo H., Otagiri M., Taguchi K.

    Journal of Pharmaceutical Sciences (Journal of Pharmaceutical Sciences)  109 ( 9 ) 2919 - 2924 2020年09月

    ISSN  00223549

     概要を見る

    © 2020 American Pharmacists Association® Daptomycin, a cyclic lipopeptide antibiotic, is clinically used for the treatment of infections caused by Gram-positive bacteria, including the methicillin-resistant Staphylococcus aureus and the vancomycin-resistant Enterococci. While daptomycin shows high plasma protein binding (90–93%), our knowledge of the binding process is not extensive. To address this issue in more detail, we characterized the binding of daptomycin to plasma proteins and the findings indicate that the association constant for the binding of daptomycin to human serum albumin (HSA) is much higher than that for α1-acid glycoprotein, another plasma protein. Daptomycin was also found to bind to a single site on HSA, which was identified as site II. The findings also suggest that the n-decanoyl moiety of daptomycin penetrates into the hydrophobic pocket of site II and that this acyl moiety interacts with Tyr411 at the entrance to site II. Due to this selective interaction with site II, daptomycin binding was significantly inhibited by drugs (ibuprofen or diazepam) and endogenous compounds (uremic toxins or fatty acids) which also strongly bind to site II. In diseased states, such an inhibition in the binding could result in the pharmacokinetics and therapeutic action of daptomycin being substantially altered.

  • Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes

    Son K., Ueda M., Taguchi K., Maruyama T., Takeoka S., Ito Y.

    Journal of Controlled Release (Journal of Controlled Release)  322   209 - 216 2020年06月

    ISSN  01683659

     概要を見る

    © 2020 Elsevier B.V. Using polyethylene glycol (PEG) to functionalize liposomes improves their stealth properties and stability in blood. However, PEG is known to induce the accelerated blood clearance (ABC) phenomenon, which occurs for multiple doses owing to anti-PEG IgM being produced after the initial injection. In this study, as an alternative to PEG, polysarcosine (PSar) was selected owing to its low antigenicity and its highly dense chains with controllable lengths, similar to PEG. Furthermore, we directly evaluate the potential of PSar for avoiding the ABC phenomenon by comparing PSar with PEG on the same liposome platform, which has similar physicochemical properties such as hydrophobic region, membrane fluidity, and size. PEG- and PSar-liposomes were prepared and characterized for comparison. PSar-liposomes showed similar physicochemical properties to PEG-liposomes in terms of size control, zeta potential, membrane polarity, and fluidity; however, ELISA results showed noticeably lower levels and faster production speeds of both IgM and IgG for PSar-liposomes than for PEG-liposomes. In addition, a pharmacokinetics experiment with multiple injections showed that PSar-PE coating of liposomes may help to circumvent the ABC phenomenon.

  • In vivo evaluation of drug dialyzability in a rat model of hemodialysis

    Fukunaga M., Kadowaki D., Mori M., Hagiwara S., Narita Y., Saruwatari J., Tanaka R., Watanabe H., Yamasaki K., Taguchi K., Ito H., Maruyama T., Otagiri M., Hirata S.

    PLoS ONE (PLoS ONE)  15 ( 6 ) e0233925 2020年06月

     概要を見る

    Copyright: © 2020 Fukunaga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. It is important to calculate the drug removal by hemodialysis (HD) for drug dosing regimens in HD patients. However, there are limited and inconsistent information about the dialyzability of drugs by HD. Therefore, the aim of our study is to evaluate drug removal by utilizing a rat model of HD (HD rat) and to extrapolate this result to the drug removal rate in HD patients. HD rats received bilateral nephrectomy and HD for 2 h. The dialysis removal of 6 drugs was evaluated in HD rats. Dialysis efficiency, plasma protein binding rate (PBR) and distribution volume (Vd) of drugs were also measured. Furthermore, we examined the correlation between the dialyzability of drug in HD rats and humans and constructed the prediction formula of the drug dialyzability in HD patients. The clearance of urea and creatinine and normalized dialysis dose in HD rats were 0.83 ± 0.07 mL/min, 0.70 ± 0.08 mL/min, and 0.13 ± 0.06, respectively. The drug dialyzability in HD rats was similar to reported clinical data except for doripenem. A higher correlation was observed between drug dialyzability in reported clinical data and HD rats which were adjusted for PBR (r2 = 0.936; p < 0.001) compared to unadjusted (r2 = 0.812; p = 0.009). Therefore, we constructed the prediction formula of the drug dialyzability in HD patients by utilizing the HD rat model and PBR. This study is useful for evaluating the dialyzability of high-risk drugs in a clinical setting and might provide appropriate preclinical dialyzability data for new drug.

全件表示 >>

総説・解説等 【 表示 / 非表示

  • The charm of protein for drug development

    Ishima Y., Taguchi K.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020年02月

    ISSN  00316903

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    薬学雑誌 138   1381 - 1389 2018年

    総説・解説(学術雑誌), 単著

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017年

    総説・解説(学術雑誌), 共著

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017年

    総説・解説(学術雑誌), 共著

  • Potential use of biological proteins for liver failure therapy.

    Taguchi K, Yamasaki K, Seo H, Otagiri M.

    Pharmaceutics. 7 ( 3 ) 255 - 274 2015年

    総説・解説(学術雑誌), 共著

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • ヘモグロビン内封リポソームを用いたシアン化物中毒解毒剤の開発

    2019年04月
    -
    2021年03月

    橋渡し研究戦略的推進プログラム シーズA, その他,  代表

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 田口 和明, 基盤研究(C), 補助金,  代表

  • 一酸化炭素結合ヘモグロビン小胞体の多機能型蘇生剤としての有用性評価

    2014年04月
    -
    2017年03月

    科学研究費補助金・若手研究B, 補助金,  代表

  • 一酸化炭素結合型ヘモグロビン小胞体の特発性肺線維症新規治療薬としての有用性評価

    2012年04月
    -
    2014年03月

    科学研究費補助金・若手研究B, 補助金,  代表

知的財産権等 【 表示 / 非表示

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    特願: 特願2020-144044  2020年08月 

    特許, 共同, 国内出願

  • 横紋筋融解症治療剤

    特許: 特許第6523842号  2019年05月

    特許, 共同, 国内出願

受賞 【 表示 / 非表示

  • 熊本大学学長賞

    2011年03月

  • 日本薬学会九州支部学術奨励賞

    2017年12月

  • 日本薬学会奨励賞

    2020年03月

    受賞区分: 国内学会・会議・シンポジウム等の賞

 

担当授業科目 【 表示 / 非表示

  • 課題研究(薬効解析学)

    2020年度

  • 演習(薬効解析学)

    2020年度

  • 卒業研究1(薬学科)

    2020年度

  • 実務実習事前学習1

    2020年度

  • 実務実習事前学習(実習)

    2020年度

全件表示 >>